Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK)
| Previous close | 177.500 |
| Open | 179.000 |
| Bid | 183.700 x N/A |
| Ask | 184.000 x N/A |
| Day's range | 177.800 - 186.400 |
| 52-week range | 60.600 - 186.400 |
| Volume | |
| Avg. volume | 398,248 |
| Market cap | 40.332B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.120 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 185.60 |
PR NewswireCEO of Kelun-Biotech Dr. Micheal Ge delivered a presentation on The 42nd JPM Annual Healthcare Conference
The 42nd J.P. Morgan Annual Healthcare Conference（"JPMHC"）2024 is taking place on January 8-11 at San Fracisco, USA, members of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK, Kelun-Biotech) senior management team participated in the conference. Dr. Micheal Ge, CEO of Kelun-Biotech, delivered a presentation about innovation strength and business progress of Kelun-Biotech.
- PR Newswire
Prof. Yongmei Yin at 2023 ESMO: SKB264 (MK-2870), an innovativeTROP2-ADC originating from Chinese biotech, achieves remarkable success in overcoming the therapeutic impasse in HR+/HER2- metastatic breast cancer
The European Society for Medical Oncology (ESMO) convened its annual meeting in Madrid, Spain, from October 20th to 24th, 2023. As the preeminent academic gathering in the field ofoncology, it brought together global experts in oncology to share the latest research findings and exchange experiences in clinical diagnosis and treatment across various tumor types. In the realm of breast cancer research, Professor Yongmei Yin from Jiangsu Province Hospital, representing the research team, delivered
- PR Newswire
Based on recent data presented at 2023 ESMO, the innovative TROP2 ADC SKB264 (MK-2870) shows promising prospects for the treatment of patients with HR+/HER2- metastatic breast cancer who have undergone multiple prior lines of therapy , and its clinical development in other solid tumors is also advancing steadily
Human trophoblastic cell surface antigen 2 (TROP2) exhibits high expression in numerous solid tumors, making it a prominent target in recent oncology studies. The progress in the development of Antibody-Drug Conjugates (ADCs) against this target has garnered significant interest in recent years. At this year's European Society for Medical Oncology (ESMO) Congress held in Madrid, Spain from October 20-24, the innovative TROP2-ADC (SKB264, MK-2870) for the treatment of hormone receptor-positive (H
